Researchers across Chile, Argentina, and the United States are making significant progress in the fight against hantavirus, a rare but deadly rodent-borne virus. Despite limited funding, recent developments offer hope for effective treatments and vaccines.
Challenges in Hantavirus Research
Hantavirus, known for its severe impact on human health, recently gained attention following an outbreak on a cruise ship. This virus, unlike novel pathogens, has been known for decades but remains underfunded due to its rarity and difficulty in transmission between humans. Researchers hope the recent attention will lead to increased investment in developing treatments and vaccines.
Dr. Fernando Tortosa from the National University of Río Negro in Argentina emphasized the importance of continued research and collaboration between healthcare workers and communities. The Andes virus, responsible for the cruise ship outbreak, is particularly concerning as it can spread between people in some cases, making it a public health issue.
Promising Treatment Developments
In Argentina, researchers are exploring the use of tocilizumab, a drug for rheumatoid arthritis, to treat hantavirus pulmonary syndrome. This severe infection, caused by both the Andes virus and the Sin Nombre virus found in North America, can lead to fatal lung complications. Initial results are promising, with four out of five patients surviving after receiving the drug in addition to standard care. However, further investigation is needed.
Efforts Toward Vaccines
Efforts to develop vaccines and antibody treatments are also underway. Chilean scientists, in collaboration with international partners, are working on using cloned antibodies from survivors to prevent infections. Although initial animal trials were successful, funding for human trials has been challenging to secure.
Meanwhile, a team led by Jay Hooper at the U.S. Army Medical Research Institute of Infectious Diseases is developing a vaccine targeting the Andes virus. Early-stage human trials have shown promising results, generating antibodies against the virus.
Overcoming Research Hurdles
Dr. Paul Bollyky from Stanford Medical Center highlights the difficulties in sustaining support for rare disease research. The sporadic nature of hantavirus outbreaks makes it challenging to conduct large-scale clinical trials and predict market demand for treatments. Despite these hurdles, researchers remain committed to finding solutions that could save lives.
Original reporting: KTBS 3 (Shreveport) — read the source article.
